Susan Froshauer is the President and Chief Executive Officer of Rib-X Pharmaceuticals, Inc. Under Dr. Froshauer's leadership, Rib-X has raised more than $123 million in private equity and grown a pipeline of clinical stage programs and an antibiotic drug discovery process to sustain the continual pipeline build. Formerly, Dr. Froshauer created a significant technology investment portfolio for Pfizer, Inc. as a member of its Strategic Alliance Group. The portfolio was designed to support Pfizer's global research and development programs and included partnerships with Arqule, Evotec, Aurora, Tripos, and Neurogen. Dr. Froshauer is the recipient of the Pfizer Central Research Award and the Connecticut Technology Council's Women of Innovation 2006 Award for Entrepreneurial Innovation and Leadership. In addition to serving on the Rib-X board, Dr. Froshauer serves on the boards of CURE and CBIA. She has also served on Connecticut's Technology Transfer and Commercialization Advisory Board of the Governor's Competitiveness Council. Dr. Froshauer holds a PhD from Harvard University and performed post-doctoral research at Yale Medical School.